ERBB2 and breast carcinoma: In human epidermal growth factor receptor 2 (HER2) receptor-positive breast cancer, there has been increased resistance against drugs (e.g., trastuzumab) used to treat this type of cancer as a result of overexpressing HER2; trastuzumab activity is disrupted by increased expression of IGF-1 receptor [12].